Antibody drug conjugates (adc) that bind to 161p2f10b proteins
AssigneeAgensys, Inc.
InventorsMICHAEL TORGOV, ROBERT KENDALL MORRISON, AYA JAKOBOVITS, JEAN GUDAS, ZILI AN
Life of this patent
Estimating the term…
Abstract
Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Claims14
An antibody drug conjugate, comprising an antibody or antigen binding fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the amino acid sequence of the VH region of SEQ ID NO:7, from 20 to 142, and the VL region of SEQ ID NO:8, from 20 to 127 and wherein said antibody is conjugated to monomethyl auristatin F (MMAF).
A method of delivering a cytotoxic agent or a diagnostic agent to a cell, comprising:
- providing MMAF(s) conjugated to an antibody or fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the amino acid sequence of the VH region of SEQ ID NO:7, from 20 to 142 and the VL region of SEQ ID NO:8, from 20 to 127, to form an antibody drug or fragment drug conjugate;
- and
- exposing the cell to the antibody drug or fragment drug conjugate.
Dependencies are inferred from the claim text.